Intrexon and Arch Pharmalabs Partner on Fermentative Production of an API to Replace Existing Process Sourced from Animals, Intexon Will Receive A Tech Access Fee, Milestone Payments, And 40% Royalty On Gross Profit
Paul Quintaro